Tazemetostat
- Generic Name
- Tazemetostat
- Brand Names
- Tazverik
- Drug Type
- Small Molecule
- Chemical Formula
- C34H44N4O4
- CAS Number
- 1403254-99-8
- Unique Ingredient Identifier
- Q40W93WPE1
- Background
Tazemetostat is a methyltransferase inhibitor used to treat metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Tazemetostat was first named in literature as EPZ-6438.
Tazemetaostat was granted FDA approval on 23 January 2020.
- Indication
Tazemetostat is indicated to treat adult and pediatric patients 16 years and older with metastatic or locally advanced epithelioid sarcoma that is not eligible for complete resection. It is also indicated to treat adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an IZH2 mutation and who have received at least 2 pri...
- Associated Conditions
- Locally Advanced Epithelioid Sarcoma, Metastatic Epithelioid Sarcoma, Refractory Follicular Lymphoma, Relapsed Follicular Lymphoma
- Associated Therapies
- -
Tazemetostat for the Treatment of Moderate to Severe COVID-19 Infection
- Conditions
- Interventions
- First Posted Date
- 2021-08-24
- Last Posted Date
- 2021-11-22
- Lead Sponsor
- Loma Linda University
- Registration Number
- NCT05018975
Tazemetostat in Malignant Peripheral Nerve Sheath Tumors
- First Posted Date
- 2021-06-08
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 24
- Registration Number
- NCT04917042
- Locations
- 🇺🇸
University of Florida, Gainesville, Florida, United States
Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC
- Conditions
- Interventions
- First Posted Date
- 2021-04-15
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 35
- Registration Number
- NCT04846478
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2021-02-21
- Last Posted Date
- 2024-03-25
- Lead Sponsor
- Epizyme, Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT04762160
- Locations
- 🇺🇸
XCancer/ Northwest Oncology & Hematology, Rolling Meadows, Illinois, United States
🇺🇸Compassionate Cancer Care, Fountain Valley, California, United States
🇺🇸USOR/ Illinois Cancer Specialists, Niles, Illinois, United States
Combining Epigenetic And Immune Therapy to Beat Cancer.
- First Posted Date
- 2021-01-12
- Last Posted Date
- 2023-03-01
- Lead Sponsor
- Institut Bergonié
- Target Recruit Count
- 173
- Registration Number
- NCT04705818
- Locations
- 🇫🇷
CHU Poitiers, Poitiers, France
🇫🇷Institut Bergonie, Bordeaux, France
🇫🇷CHRU Brest, Brest, France
Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2020-11-10
- Last Posted Date
- 2024-02-21
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 13
- Registration Number
- NCT04624113
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels
- Conditions
- Interventions
- First Posted Date
- 2020-09-03
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Epizyme, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT04537715
- Locations
- 🇪🇸
Onkologikoa, Donostia, Gipuzkoa, Spain
🇺🇸California Cancer Associates for Research and Excellence, Inc. (cCARE), Encinitas, California, United States
🇺🇸Northwestern University-Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, United States
A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function
- Conditions
- Interventions
- First Posted Date
- 2020-01-27
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Epizyme, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT04241835
- Locations
- 🇺🇸
Rutgers Cancer Institute, New Brunswick, New Jersey, United States
🇺🇸Florida Cancer Specialists & Research Institute, Lake Mary, Florida, United States
🇺🇸Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, United States
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
- First Posted Date
- 2020-01-13
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Epizyme, Inc.
- Target Recruit Count
- 612
- Registration Number
- NCT04224493
- Locations
- 🇦🇺
GenesisCare - St Andrew's, Adelaide, Australia
🇮🇹Ospedale Maggiore Policlinico, Fondazione IRCCS Ca' Granda, Milano, Italy
🇮🇹Ospedale San Gerardo, ASST di Monza, Monza, Italy
Tazemetostat Expanded Access Program for Adults With Epithelioid Sarcoma
- Conditions
- First Posted Date
- 2020-01-13
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Epizyme, Inc.
- Registration Number
- NCT04225429
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.